Synopsis:
The company reported strong growth in Q2FY26, with revenue up 20.74% YoY and 10.66% QoQ to Rs. 2,096 Cr, net profit rising 19.77% YoY and 69% QoQ to Rs. 103 Cr.
The shares of the Mid-Cap company, specializing in the design, manufacturing, branding, and omnichannel retail of eyewear products, including prescription eyeglasses, sunglasses, contact lenses, and accessories jumped upto 5 percent following their Q2 results with a 69 percent rise in profit QoQ.
With a market capitalization of Rs. 72,864.55 Crores on Monday, the shares of Lenskart Solutions Ltd rose upto 5.1 percent, reaching a high of Rs. 432.25 compared to its previous closing price of Rs. 411.20.
What Happened
Lenskart Solutions Ltd, engaged in the design, manufacturing, branding, and omnichannel retail of eyewear products, including prescription eyeglasses, sunglasses, contact lenses, and accessories, has announced its Q2 results as follows:
Its Revenue from operations rose by 20.74 percent YoY from Rs. 1,736 Crores in Q2FY25 to Rs. 2,096 Crores in Q2FY26, and it rose by 10.66 percent QoQ from Rs. 1,894 Crores in Q1FY26 to Rs. 2,096 Crores in Q2FY26.
Its Net Profit YoY rose by 19.77 percent from Rs. 86 Crores in Q2FY25 to Rs. 103 Crores in Q2FY26, and in QoQ from Rs. 61 crores in Q1FY26 it rose by 69 percent to Rs. 103 Crores in Q2FY26. The earnings per share (EPS) for the quarterly period stood at Rs. 1.24, compared to Rs. 0.78 in the previous quarter.
Segment-wise, India continued to anchor Lenskart’s business with Rs 1,230.6 crore in revenue during the quarter, higher than both the previous quarter and the year-ago period. International markets also delivered strong growth, contributing Rs 879.6 crore, up from Rs 736.5 crore in Q1 and Rs 658.3 crore in Q2 FY25.
Brokerage view on Lenskart Results
Last week, Jefferies initiated coverage on the stock with a “buy” rating and a ₹500 price target, implying 21% upside. The firm highlighted that the second quarter marked the start of the company’s growth phase, driven by tech and supply chain efficiencies, while AI now integrates across operations, and a smart eyewear launch is imminent.
Jefferies also noted strong store potential in India and measured global expansion, describing the company as still being at “day zero,” with management focused on long-term growth and building investor trust through consistent execution and transparency.
Company Overview & Others
Lenskart Solutions Ltd launched its Initial Public Offering (IPO) to support funding for growth and expansion. The issue comprises a fresh issue of 5.35 crore shares aggregating to Rs. 2,150.00 crore and an offer for sale of 12.76 crore shares aggregating to Rs. 5,128.02 crore, with a face value of Rs. 2 per share.
Lenskart Solutions Ltd., established in 2008, is a technology-focused eyewear company that designs, manufactures, brands, and retails prescription eyeglasses, sunglasses, contact lenses, and accessories. India serves as its primary market, and as per the Redseer Report, the company recorded the highest volume of prescription eyeglasses sold in India during FY 2025.
As of March 31, 2025, Lenskart operated a total of 2,723 stores globally—2,067 in India and 656 overseas. Of these, 1,757 are company-owned and 310 are franchised within India. The company also provides remote eye testing services through 136 optometrists across 168 stores in India and select international locations such as Japan and Thailand, enhancing accessibility and convenience for customers.
Its manufacturing and assembly operations are primarily based in Bhiwadi and Gurugram, supported by regional facilities in Singapore and the UAE. This integrated infrastructure enables next-day delivery in 40 Indian cities and 3-day delivery in 69 cities for single-vision prescription eyewear.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
